–
88/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →Growth Hormone · GHRP
GHRP-2
Released: Last reviewed:
GHRP-2 is a synthetic growth hormone-releasing peptide (hexapeptide) that stimulates pituitary GH release through the ghrelin receptor. Used in research settings and by compounding pharmacies.
GHRP-2 at a glance
GHRP-2 is a synthetic growth hormone-releasing peptide (hexapeptide) that stimulates pituitary GH release through the ghrelin receptor. Used in research settings and by compounding pharmacies. Mechanism: GHRP / GH secretagogue. Typical route: Subcutaneous. FDA status: Not FDA-approved. Used in clinical research and dispensed by compounding pharmacies.
Drug classGHRP / GH secretagogue
Half-life~30 minutes
RouteSubcutaneous
Common dosing100-300 mcg, 2-3x/day
FDA statusNot approved
Available throughSee the dated FDA status notice above
Mechanism of action
GHRP-2 binds the growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor) on pituitary somatotrophs, stimulating endogenous growth hormone release. Effects are most pronounced when combined with a growth hormone-releasing hormone (GHRH) analog such as CJC-1295.
Dosing reference
Subcutaneous: 100-300 mcg, two to three times daily, often combined with CJC-1295 1295 100 mcg per dose. Standard protocols dose on an empty stomach and around exercise or before bed.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Not FDA-approved. Used in clinical research and dispensed by compounding pharmacies.
U.S. telehealth providers that work with GHRP-2
–
80/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →–
85/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →–
76/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →Related growth hormone secretagogues peptides
Frequently asked questions about GHRP-2
How does GHRP-2 compare to GHRP-6?
GHRP-2 stimulates less appetite (less ghrelin-like effect) and is generally preferred when patients want GH stimulation without the increased hunger that GHRP-6 commonly causes.
Is GHRP-2 worth using with CJC-1295?
The combination (GHRP + GHRH analog) produces a larger and more sustained GH pulse than either alone. CJC-1295/Ipamorelin is a more commonly prescribed pairing today.
References
- GH releasing peptides--structure and kinetics. J Pediatr Endocrinol. 1993;6(1):21-31. PMID: 8348220
- Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004;89(5):2290-2300. PMID: 15126555
Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.